BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36965457)

  • 1. The association between white matter hyperintensities and amyloid and tau deposition.
    Alban SL; Lynch KM; Ringman JM; Toga AW; Chui HC; Sepehrband F; Choupan J;
    Neuroimage Clin; 2023; 38():103383. PubMed ID: 36965457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities.
    Cha WJ; Yi D; Ahn H; Byun MS; Chang YY; Choi JM; Kim K; Choi H; Jung G; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY
    Alzheimers Res Ther; 2024 Mar; 16(1):50. PubMed ID: 38454444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
    Eloyan A; Thangarajah M; An N; Borowski BJ; Reddy AL; Aisen P; Dage JL; Foroud T; Ghetti B; Griffin P; Hammers D; Iaccarino L; Jack CR; Kirby K; Kramer J; Koeppe R; Kukull WA; La Joie R; Mundada NS; Murray ME; Nudelman K; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Rogalski E; Salloway S; Sha S; Turner RS; Wingo TS; Wolk DA; Womack K; Beckett L; Gao S; Carrillo MC; Rabinovici G; Apostolova LG; Dickerson B; Vemuri P;
    Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S89-S97. PubMed ID: 37491599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
    Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
    J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linking white matter hyperintensities to regional cortical thinning, amyloid deposition, and synaptic density loss in Alzheimer's disease.
    Zhang J; Chen H; Wang J; Huang Q; Xu X; Wang W; Xu W; Guan Y; Liu J; Wardlaw JM; Deng Y; Xie F; Li B
    Alzheimers Dement; 2024 Jun; 20(6):3931-3942. PubMed ID: 38648354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. White matter hyperintensities: relationship to amyloid and tau burden.
    Graff-Radford J; Arenaza-Urquijo EM; Knopman DS; Schwarz CG; Brown RD; Rabinstein AA; Gunter JL; Senjem ML; Przybelski SA; Lesnick T; Ward C; Mielke MM; Lowe VJ; Petersen RC; Kremers WK; Kantarci K; Jack CR; Vemuri P
    Brain; 2019 Aug; 142(8):2483-2491. PubMed ID: 31199475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment.
    Guzman VA; Carmichael OT; Schwarz C; Tosto G; Zimmerman ME; Brickman AM;
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S124-31. PubMed ID: 23375566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. White matter hyperintensity patterns: associations with comorbidities, amyloid, and cognition.
    Bachmann D; von Rickenbach B; Buchmann A; Hüllner M; Zuber I; Studer S; Saake A; Rauen K; Gruber E; Nitsch RM; Hock C; Treyer V; Gietl A
    Alzheimers Res Ther; 2024 Apr; 16(1):67. PubMed ID: 38561806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
    Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
    Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease.
    Walsh P; Sudre CH; Fiford CM; Ryan NS; Lashley T; Frost C; Barnes J;
    Neurobiol Aging; 2020 Jul; 91():5-14. PubMed ID: 32305782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White matter hyperintensities and cognition across different Alzheimer's biomarker profiles.
    Lam S; Lipton RB; Harvey DJ; Zammit AR; Ezzati A;
    J Am Geriatr Soc; 2021 Jul; 69(7):1906-1915. PubMed ID: 33891712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment.
    Tosto G; Zimmerman ME; Hamilton JL; Carmichael OT; Brickman AM;
    Alzheimers Dement; 2015 Dec; 11(12):1510-1519. PubMed ID: 26079417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions.
    Weaver NA; Doeven T; Barkhof F; Biesbroek JM; Groeneveld ON; Kuijf HJ; Prins ND; Scheltens P; Teunissen CE; van der Flier WM; Biessels GJ;
    Neurobiol Aging; 2019 Dec; 84():225-234. PubMed ID: 31500909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Life Span.
    Luo J; Ma Y; Agboola FJ; Grant E; Morris JC; McDade E; Fagan AM; Benzinger TLS; Hassenstab J; Bateman RJ; Perrin RJ; Gordon BA; Goyal M; Strain JF; Yakushev I; Day GS; Xiong C;
    Neurology; 2023 Jul; 101(2):e164-e177. PubMed ID: 37202169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    van Waalwijk van Doorn LJC; Ghafoorian M; van Leijsen EMC; Claassen JAHR; Arighi A; Bozzali M; Cannas J; Cavedo E; Eusebi P; Farotti L; Fenoglio C; Fortea J; Frisoni GB; Galimberti D; Greco V; Herukka SK; Liu Y; Lleó A; de Mendonça A; Nobili FM; Parnetti L; Picco A; Pikkarainen M; Salvadori N; Scarpini E; Soininen H; Tarducci R; Urbani A; Vilaplana E; Meulenbroek O; Platel B; Verbeek MM; Kuiperij HB
    J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. White Matter Hyperintensity Volume and Amyloid-PET Synergistically Impact Memory Independent of Tau-PET in Older Adults Without Dementia.
    Edwards L; Thomas KR; Weigand AJ; Edmonds EC; Clark AL; Walker KS; Brenner EK; Nation DA; Maillard P; Bondi MW; Bangen KJ;
    J Alzheimers Dis; 2023; 94(2):695-707. PubMed ID: 37302031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. White matter hyperintensities influence distal cortical β-amyloid accumulation in default mode network pathways.
    Ali DG; Bahrani AA; El Khouli RH; Gold BT; Jiang Y; Zachariou V; Wilcock DM; Jicha GA
    Brain Behav; 2023 Oct; 13(10):e3209. PubMed ID: 37534614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
    Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
    Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced [
    Moscoso A; Grothe MJ; Schöll M;
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2283-2294. PubMed ID: 33475761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-sectional Associations of β-Amyloid, Tau, and Cerebrovascular Biomarkers With Neurodegeneration in Probable Dementia With Lewy Bodies.
    Ferreira D; Przybelski SA; Lesnick TG; Schwarz CG; Diaz-Galvan P; Graff-Radford J; Senjem ML; Fields JA; Knopman DS; Jones DT; Savica R; Ferman TJ; Graff-Radford N; Lowe VJ; Jack CR; Petersen RC; Westman E; Boeve BF; Kantarci K
    Neurology; 2023 Feb; 100(8):e846-e859. PubMed ID: 36443011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.